克尔来福(科兴)与复必泰(辉瑞-BioNTech)自报反应原性比较:一项强化监测的前瞻性队列研究
该前瞻性队列研究通过在线问卷从首次接种日至第二剂后两周(11个时间点)比较克尔来福与复必泰的自报不良反应。共纳入2098名计划完成第14天调查的参与者,46.2%接种复必泰。复必泰组801人(82.7%)报告不良反应,克尔来福组543人(48.1%)报告;校正分析显示克尔来福与任何不良反应、局部不良反应、全身不良反应的odds均显著低于复必泰。
要点
- 克尔来福组任何不良反应报告率48.1%,复必泰组82.7%。
- 校正后克尔来福任何不良反应的AOR=0.17(95%CI 0.15-0.20)。
- 未发现多病共存状态、高龄或性别的显著效应修饰。
核心结论
- 这项比较新冠疫苗反应原性的上市后研究表明,与复必泰相比,接种克尔来福后自报不良反应的风险更低。
研究设计与样本
- 采用前瞻性队列研究设计,使用在线问卷从首次接种日随访至第二剂后两周(共11个时间点)。
- 共纳入2098名计划完成第14天调查的参与者,其中46.2%接种复必泰。
- 主要结局为不良反应(任何 vs 无),次要结局为不良反应亚类(局部、全身和严重过敏反应)。
- 检验了多病共存状态、高龄和性别可能的效应修饰。
主要发现
- 整个随访期间,复必泰组801人(82.7%)报告不良反应,克尔来福组543人(48.1%)报告不良反应。
- 校正分析显示,与复必泰相比,克尔来福与任何不良反应的odds降低83%相关(AOR=0.17,95%CI 0.15-0.20)。
- 克尔来福与局部不良反应的odds降低92%相关(AOR=0.08,95%CI 0.06-0.09)。
- 克尔来福与全身不良反应的odds降低76%相关(AOR=0.24,95%CI 0.16-0.28)。
- 未发现显著的效应修饰。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: CoronaVac (Sinovac) Covid-19 vaccine has recently been approved for emergency use by the World Health Organization. However, data on its reactogenicity in real-world settings is scant. This study aimed to compare self-reported post-vaccination adverse reactions between CoronaVac and Comirnaty (Pfizer-BioNTech). METHODS: We adopted a prospective cohort study design using online surveys from the day of first-dose vaccination with intensive follow-up through two weeks after the second dose (11 time points). The primary outcome was adverse reactions (any versus none) and secondary outcomes were the sub-categories of adverse reactions (local, systemic, and severe allergic reactions). Potential effect modification across multimorbidity status, older age, and sex was examined. RESULTS: In total, 2,098 participants who were scheduled to complete the 14th-day survey were included, with 46.2% receiving Comirnaty. Retention rate two weeks after the second dose was 81.0% for the CoronaVac group and 83.6% for the Comirnaty group. Throughout the follow-up period, 801 (82.7%) of those receiving Comirnaty and 543 (48.1%) of those receiving CoronaVac reported adverse reactions. Adjusted analysis suggested that compared with Comirnaty, CoronaVac was associated with 83%-reduced odds of any adverse reactions [adjusted odds ratio (AOR) = 0.17, 95% confidence interval (CI) 0.15-0.20], 92%-reduced odds of local adverse reactions (AOR = 0.08, 95% CI 0.06-0.09), and 76%-reduced odds of systemic adverse reactions (AOR = 0.24, 95% CI 0.16-0.28). No significant effect modification was identified. CONCLUSION: This post-marketing study comparing the reactogenicity of Covid-19 vaccines suggests a lower risk of self-reported adverse reactions following vaccination with CoronaVac compared with Comirnaty.
引用
- Lai FTT, Leung MTY, Chan EWW, et al. Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring. Vaccine. 2022. PMID: 35140013. doi:10.1016/j.vaccine.2022.01.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。